ENOV

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).

Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 49.00 USD with a low forecast of 44.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Enovis Corp revenue for the last quarter amounts to 548.91M USD, increased 8.65 % YoY.

Enovis Corp. EPS for the last quarter amounts to -9.99 USD, increased 1652.63 % YoY.

Enovis Corp (ENOV) has 7367 emplpoyees as of December 15 2025.

Today ENOV has the market capitalization of 1.51B USD.